{"SPADE_UN_17490": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_17490", "Peptide Name": "Longicalycinin A linear", "Source": "Synthetic", "Family": "", "Gene": "Not found", "Sequence": "FYPFG", "Sequence Length": 5, "UniProt Entry": ["http://www.uniprot.org/uniprot/Notavailable"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Anticancer"], "Target Organism": "Tumor cells:HepG2 (IC50=9.18 ± 0.0014 μg/mL); HT-29 (IC50=9.61 ± 0.0007 μg/mL)", "Hemolytic Activity": "Not available", "Cytotoxicity": "Not available", "Binding Target": "Not available", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C34H39N5O7", "Mass": 629.7, "PI": 5.52, "Net Charge": 0, "Hydrophobicity": 0.46, "Half Life": "Mammalian:1.1 hourYeast:3 minE.coli:2 min", "Literature": [{"Title": "Structure-activity relationship studies of Longicalcynin A analogues, as anticancer cyclopeptides", "Pubmed ID": "31747558", "Reference": "Chem Biol Interact. 2020 Jan 5;315108918.", "Author": "Gholibeikian M, Bamoniri A, HoushdarTehrani MH, Fatemeh Mirjalili BB, Bijanzadeh HR.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=31747558"}, {"Title": "Synthetic and pharmacological studies on longicalycinin A", "Pubmed ID": "", "Author": "Dahiya R"}], "Frequent Amino Acids": "FGP", "Absent Amino Acids": "ACDEHIKLMNOQRSTUVW", "Basic Residues": 0, "Acidic Residues": 0, "Hydrophobic Residues": 4, "Polar Residues": 1, "Positive Residues": 0, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_12875", "Similarity": 1.0, "Sequence": "RFRPPIRRPPIRPPFYP"}, {"SPADE_ID": "SPADE_UN_15561", "Similarity": 1.0, "Sequence": "RFRRPIRRRPIRPPFYP"}, {"SPADE_ID": "SPADE_UN_15567", "Similarity": 1.0, "Sequence": "RFRWPIRRRPIRPPFYP"}]}}}